Background. To better understand the role of race/ethnicity in survival after acute myocardial infarction, we compared clinical and laboratory data, response to thrombolytic therapy, and clinical outcome in 2885 patients participating in the Thrombolysis in Myocardial Infarction Phase II (TIMI II) Trial among three groups of patients (2564 whites, 174 blacks, and 147 Hispanics).
C ontrary to the prevailing beliefs of decades past, coronary heart disease is now known to be the leading cause of death among black and Hispanic as well as white Americans.' In blacks, mortality after myocardial infarction (MI) is an area of particular concern, as poor rates of survival have been reported among black patients in the first 12 to 24 months after MI.2-8 The relative contributions of predisposing cardiovascular risk factors, other comorbidities, access to appropriate health care, and other factors to this excess mortality have been debated. Early studies suggested that Hispanic American patients have a relatively low mortality after MI, although Hispanic Americans have an unfavorable prevalence of risk factors for coronary heart disease.9-' 2 The poor survival observed among black patients is based on data collected before intravenous administration of thrombolytic agents became widely accepted as practical and highly effective in the treatment of acute myocardial infarction (AMI). A series of national and international cooperative studies of the 1980s established thrombolysis-supplemented with percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery for patients with persistent ischemia-as the therapy of choice for AMI in patients without contraindications. [13] [14] [15] [16] [17] [18] [19] [20] The Thrombolysis in Myocardial Infarction Phase II (TIMI II) Trial offers an important opportunity to gain further insight into the mortality among black patients with MI and the morbidity and mortality patterns among Hispanic American patients. 440 27.1 6.0 49 28.7 5.3 21 29.9 5.9
*Probability values for racial differences after adjustment for sex with logistic regression for binary variables and ANOVA for continuous variables.
tHigh school or higher.
Methods unfavorable outcome if they did not present with any of The TIMI II trial was performed in 24 clinical centers the following characteristics: (1) previous myocardial across the United States. The study design and patient infarction, (2) age >70 years, (3) systolic blood pressure inclusion/exclusion criteria for the trial have been de-<100 and sinus tachycardia .100 beats per minute, (4) scribed previously in detail. 13 Eligible patients were less atrial fibrillation or flutter, (5) pulmonary rales in one than 76 years of age, had ischemic cardiac pain lasting at third or more of the lung fields, (6) pulmonary edema least 30 minutes with confirmatory ST-segment elevaon chest x-ray, (7) cardiogenic shock, and (8) anterior tions of at least 0.1 mV in two or more contiguous ECG location of MI. leads, had no contraindication to thrombolytic therapy, Racial/ethnic identity was determined according to and were able to receive recombinant tissue plasmino-each patient's preferred designation. The present study gen activator (rt-PA) within 4 hours of symptom onset. focuses on the TIMI II clinical centers that recruited at Patients were identified as being at low risk for an least two minority (black and/or Hispanic) patients. tMagnitude of racial differences for "current smoker" category depends on sex of the patient (interaction, P<.001). Data collected included a standardized initial medical history and physical examination, daily clinical assessment of progress and/or complications, and rest-exercise radionucide ventriculography using 9Tc-labeled autologous red cells.13 Baseline information for some variables was unavailable for a small number of patients. Laboratory examination of blood specimens including baseline and postthrombolysis measurement of fibrinogen, fibrin/fibrinogen degradation products, rt-PA antigen, and plasminogen have been described previously.14
Treatment Protocol
The procedures for administration of rt-PA in TIMI II have been reported.'3 The rt-PA dose was changed from 150 to 100 mg after an unacceptably high incidence of intracranial hemorrhage was noted at the higher dose.15-'7 Included in the present analysis are 421 patients who were enrolled in a 150-mg rt-PA treatment protocol and 2464 patients who were enrolled in a 100-mg rt-PA protocol. Randomization and Treatment Assignment Intravenous heparin therapy was begun at the start of rt-PA infusion with an initial 5000-U bolus; continuous infusion rates were adjusted to maintain the activated partial thromboplastin time between 1.5 and 2.0 times control. In patients randomly assigned to the invasive strategy, the heparin infusion was adjusted according to protocol at the time of cardiac catheterization to reduce bleeding risks associated with arterial cannulation. Lidocaine and oral aspirin therapy were administered according to standardized guidelines.13"15
Percutaneous Transluminal Coronary Angioplasty
Patients randomly assigned to the invasive strategy (n=1285 whites, 84 blacks, and 86 Hispanics) were to have coronary and left ventricular angiography 18 to 48 hours after initiation of the rt-PA infusion. PTCA was performed (n=706 whites, 35 blacks, and 46 Hispanics) at this time if technically and clinically feasible; if the patient's anatomy was not suitable for angioplasty, CABG was performed if indicated. p-Blocker Therapy Patients eligible for enrollment in the TIMI IIB substudy of 3-blocker therapy (n= 1134 whites, 83 blacks, and 76 Hispanics) were randomly assigned to either immediate intravenous (n=562 whites, 39 blacks, and 46 Hispanics) or delayed oral administration of metoprolol (n=572 whites, 44 blacks, and 30 Hispanics). Criteria for inclusion/ exclusion and the details of P-blocker therapy have been described in detail previously.2'
Statistical Methods
Differences among groups in clinical and angiographic characteristics were tested using the x2 test for categorical variables and ANOVA for continuous variables.22 Event rates were computed using the Kaplan-Meier method, and differences were tested using the log rank statistic. These analyses were performed using Statistical Analysis System (sAs) programs.23 Cox proportional hazards regression models were used to compute relative risks and adjusted comparisons of the event rates among the three patient groups. Comparisons were adjusted for sex, age, current smoking status, anterior MI, history of hypertension, history of diabetes, and site of enrollment. The Cox Model analyses were performed using the Bio Medical Data Programs (BMDP) statistical software. 24 With the numbers of black and Hispanic patients and cardiac events in the study, there is adequate statistical power to detect only differences that are twofold or larger in cardiac event rates among the three groups. To adjust for multiple testing, two-sided probability values between .01 and .001 provide some evidence, and values <.001 provide strong evidence of differences. Analyses are based on a data file containing information available as of January 1991.
Results

Baseline Characteristics
Men predominated among the patients of all three subgroups, but women made up a larger proportion of the black patients compared with the other groups (Table 1) . Black and Hispanic patients were generally younger and less educated than white patients. Three coronary heart disease risk factors (current smoking, history of hypertension, and history of diabetes mellitus) occurred more frequently among the two minority groups ( Table 2 ). The black patients had the highest percentages of current smokers (62.1%), history of hypertension (55.8%), and history of diabetes mellitus (22.4%); diuretic therapy was more frequent among black patients than white or Hispanic patients. The magnitude of racial differences in the percentages of 15 .09 26 
Features ofAcute Myocardial Infarction
A similar percentage of each of the three groups was classified as "not low risk" at the time of entry into TIMI II (Table 3) . Anterior MI was more frequently observed in both the black and Hispanic patients than in the white patients, and the largest percentage of patients with anterior MI was observed among Hispanic patients. The differences in percentages with a history of congestive heart failure (percentage for whites, 2.8; blacks, 4.0; Hispanics, 2.7; P=.65) and the frequency of pulmonary rales on admission could be expected by chance. Similar percentages of each patient group had ongoing chest pain at the time of hospital presentation. Also, the mean time between onset of pain to study entry was similar among the groups.
Hematologic Parameters
Total white blood cell counts for black patients (9.7x103/mm3) were lower (P<.001) than for white (11.3x103/mm3) or Hispanic patients (11.4x103/mm3).
The average hematocrit was also lowest among black patients. Data on baseline and posttreatment fibrinolytic activity here are presented for patients receiving the 100-mg dose of rt-PA (Table 4 ). Among the three patient groups, black patients had both higher baseline levels of fibrinogen and a more pronounced fall in plasma fibrinogen 5 hours after thrombolytic therapy. This occurred despite the similarity of rt-PA dose by weight between black and white patients, the higher dose per kilogram given to Hispanic patients (P<.001), and the slightly higher rt-PA plasma levels in Hispanic patients compared with the other two groups (data not shown).
Hemorrhagic Events
For patients receiving the 100-mg dose of rt-PA, no important differences in the frequency of hemorrhagic complications ( Table 5 ) were noted among the groups. tPercentages are based on the number of patients randomized to invasive strategy in each group. tTIMI grade 2 or 3 flow.
The higher complication rate seen among invasive strategy patients is consistent with earlier reports from TIMI.14
Angiographic Variables in Patients Assigned to Invasive Therapy
Angiographic data are presented in Table 6 . Among patients receiving the protocol catheterization, the differences in percentages with patent infarct-related arteries could be attributed to chance. On assessment of left ventricular systolic function using contrast ventriculography 18 to 48 hours after study entry, more black and Hispanic patients than white patients had ejection fractions <35% (P=.005). The left anterior descending coronary artery was the infarct-related artery with frequency corresponding to the frequencies of electrocardiographic anterior infarctions in the subgroups.
Among patients randomly assigned to the invasive strategy, the distribution in the performance status of the protocol PTCA was similar among the groups after adjustment for sex, age, smoking status, anterior infarction, history of hypertension, history of diabetes, and site of enrollment (P=.27; Table 7 ).
Clinical Follow-up: Mortality and Morbidity
The mortality in black patients at 1 year after MI was somewhat greater than in other groups; however, this difference was diminished when adjustment was made for differences in baseline characteristics ( Table 8 ). The adjusted relative risk of dying at 1 year for black patients compared with white patients was estimated at 1.1 (99% confidence interval: 0.6 to 2.2) and for Hispanic patients at 0.8 (99% confidence interval: 0.3 to 2.1). The adjusted risks for reinfarction and the combined end points of death, reinfarction, or readmission were similar among the three groups.
For whites and Hispanics, over one half of the deaths occurred in the first 3 weeks after MI and over 60% of deaths had occurred by week 6. Among black patients in TIMI II, more than one half of the 1-year mortality occurred between 6 weeks and 1 year from study entry ( Table 9 ). A large majority of the deaths (72.3% whites, 75.0% blacks, 75.0% Hispanics) in all three groups were cardiac in origin.
Occurrence of death and death or MI by 6 weeks are presented in Table 10 according to race, sex, and treatment. There was no evidence that differences between the invasive and conservative strategies in mortality (P=.06) or death or MI (P=.16) varied among subgroups defined by race and sex.
Discussion
The present analysis involving 2885 patients from 21 of the 24 clinical sites participating in TIMI II suggests that Hispanic and black Americans may have prognoses similar to white patients after AMI treated with thrombolytic therapy. The classic coronary artery disease risk factors of hypertension, diabetes, and smoking were more prevalent in the black and Hispanic MI patients than in the white group. Black MI patients had higher baseline fibrinogen levels and demonstrated a greater reduction of these levels in response to rt-PA when compared with other TIMI patients but did not have an increase in bleeding complications. On protocol catheterization (18 to 48 hours after randomization), infarctrelated artery patency rates were similar among the three groups, and there was no large difference in mortality or morbidity among the three groups of patients at 1 year after MI. 
Ethnicity and Survival After MI
There is increasing recognition that patterns of coronary heart disease morbidity and mortality vary among racial groups.1-12 Past investigations have reported significantly higher age-adjusted mortality after MI among black patients. Before the era of thrombolytic intervention, special therapeutic interventions improved black patients' survival but did not eliminate excess mortality among the black patients.
Haywood6 showed that blacks receiving (-blockers in the Beta-blocker Heart Attack Trial (BHAT) had a higher mortality than the white patients receiving placebo even though the (-blocker therapy was efficacious compared with placebo. Hypertension seemed to be the key correlate to poor prognosis. The Multicenter Investigation of the Limitation of Infarct Size (MILIS) study also showed less favorable outcomes for black patients, especially black women, than for white patients after MI.8 Adjustment for 10 baseline risk variables did not eliminate this discrepancy between black and white women in the MILIS study.
In contrast, in TIMI II, the trend suggesting increased mortality in black patients did not remain after adjustment for baseline characteristics. The present TIMI II findings are also distinct in that no differences among the three populations had emerged by 1 year. Although the present study is limited by the number of black patients enrolled, it represents the largest number of black patients treated with thrombolytic therapy in a clinical investigation in the United States. *Comparisons adjusted for sex, age, smoking status, anterior myocardial infarction, history of hypertension, history of diabetes, and clinical site of enrolment, using the proportional hazards model. white patients include the following: (1) selection of patients with good prognosis, (2) equal efficacy of the thrombolytic agent rt-PA in black patients, and (3) ready access to effective intensive care.
Success of Thrombolytic Strategy Among
In TIMI II, exclusion criteria were designed to select appropriate patients for the study and also may have affected the observed mortality. For example, the TIMI II exclusion criteria eliminated patients with a large elevation in blood pressure or history of uncontrolled hypertension (ie, any recording of systolic pressure >180 mm Hg or diastolic pressure >110 during presentation or a history of uncontrolled hypertension before entry). Since blacks have a higher incidence than whites or Hispanics of severe or uncontrolled hypertension, this exclusion criterion may have resulted in the selection of less complicated cases among the black MI patients. The exclusion on the basis of severity of hypertension probably would have less impact on selection of white or Hispanic patients.
The possibility of differences in the pharmacological effects of rt-PA in black patients is intriguing. Differences in baseline hemostatic factors and in response to rt-PA infusion were noted. The larger drop in fibrinogen levels among black MI patients suggests a greater sensitivity to rt-PA. Data from the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial have suggested that there are differences in patency rates 90 minutes after rt-PA infusion and that hemorrhagic complications may be greater in black patients receiving rt-PA. 25 However, TIMI II found no difference according to race in patency rates at 18 to 48 hours after rt-PA infusion. Furthermore, hemorrhagic complications were not more frequent in black patients than in white patients in TIMI II.
Timeliness and quality of care may be critical. Numerous studies have shown that there are significant barriers to early intervention among the black American population.1'26-29 The impact of socioeconomic status (disproportionately low among black Americans), medical insurance, transportation, symptom perception, and patient behavior have been shown to impede timely care for acute health problems. Furthermore, there is evidence that state-of-the-art care, particularly involving interventional revascularization (ie, surgery and/or angioplasty) may be underutilized in this population.27'29 The TIMI II study, through its protocol requirement of "treatment within 4 hours of symptom onset," selected patients who presented promptly for medical care and effectively provided access and stateof-the-art care to all patients, including revascularization with PTCA or CABG if indicated.30 This removal of access barriers could be a contributor to the similarity of the 1-year mortality figures for all three groups in the TIMI II study.
Hispanic Patients: Post-MI Survival
Despite having high prevalences of all of the classic risk factors for coronary heart disease, Hispanic patients are less likely to die of cardiovascular disease than members of the other major American racial groups.110"11 A low incidence of MI has been cited as a reason for the low mortality associated with cardiovascular disease among Hispanic patients; a more favorable prognosis after MI has not been observed previously." Although the TIMI II data did not show a large survival advantage for Hispanic patients, there was an intriguing trend toward better outcomes for Hispanic patients than for others. However, the low overall event rates (ie, death, MI, rehospitalization) during the first year re- 
Complications of Thrombolytic Therapy
Thrombolytic agents did not lead to excess hemorrhagic complications in either black or Hispanic patients compared with white patients in the TIMI II trial. Preliminary data from the TAMI study suggested a greater risk of hemorrhagic complications after infusion in black patients, secondary to more pronounced fibrinolysis.25 No excess in actual hemorrhagic events was reported, but a greater number of transfusions of more than 2 units, ordered by the attending physicians, was observed.25 In TAMI, however, baseline hematocrits were not reported. In TIMI II (Table 3 ) and in other studies,31 baseline hematocrit values in black patients have been observed to be lower than in white patients. Since clinicians often transfuse when the hematocrit falls to approximately 30%, it is possible that, although blood losses are similar in the black and white patients, the black patients are more frequently transfused because of lower baseline hematocrit values.
Limitations of the Study
The most important limitation in this comparison of racial and ethnic groups is the number of minority patients studied. Although TIMI II included a larger number of minority patients than other clinical trials, the number of minority patients and clinical events observed does not make it possible to exclude differences smaller than doubling of mortality or the frequency of death or MI. More research on heart disease in minority patients is needed. This report only covers the first year after MI; important differences in morbidity and mortality could emerge in later years but are unlikely to be caused by treatment effects.
It is possible that the TIMI II eligibility criteria and patient self-selection of medical center resulted in a study population of white, black, and Hispanic patients more similar to each other than the general white, black, and Hispanic populations in the United States. The TIMI II comparisons could underestimate differences in the broader population of MI patients but still be valid for patients for whom thrombolytic therapy would be indicated.
It is important to acknowledge the limitations of racial/ethnic categorizations in the United States, given the well-known heterogeneity of Hispanic, black, and white American populations. Black and Hispanic patients in TIMI II were from several different regions of the United States and may have had different countries of origin. Detailed characterization of patient ancestry is difficult. There is no information available in TIMI II on the specific ancestry of white, black, or Hispanic patients. However, race/ethnicity remain useful concepts in judging the impact of therapeutic interventions, given the noted differences among these groups in prognosis after AMI observed in many past studies.
Conclusions
The data from TIMI II suggest that thrombolysis could be associated with favorable outcomes after AMI regardless of the patient's race. Deaths among black patients compared with white patients were no more frequent than could be expected by chance. Despite a more pronounced fibrin(ogen)olysis, the risk (eg, hemorrhagic event) versus benefit (eg, survival and preservation of left ventricular function) ratio appears to be no different for black patients than for others. Hispanic patients have outcomes after thrombolysis for MI at least as good as the rest of the TIMI II patient population.
